Navigation Links
ADVENTRX Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference on May 17
Date:5/10/2010

SAN DIEGO, May 10 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that the Company's Chief Executive Officer, Brian M. Culley, will present at the Rodman & Renshaw Annual Global Investment Conference on Monday, May 17, 2010, at 11:05 a.m. local time (6:05 a.m. Eastern time), in the Albemarle Suite at the Grosvenor House Hotel in London.

Interested parties can access a live audio webcast and slide presentation on the ADVENTRX Pharmaceuticals Web site at www.adventrx.com.  An archived presentation will be available on the Web site for 30 days.

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a specialty pharmaceutical company whose product candidates are designed to improve the performance of existing cancer treatments by addressing limitations associated principally with their safety and use.  More information can be found on the Company's Web site at www.adventrx.com.


'/>"/>
SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
2. ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
3. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
4. ADVENTRX Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of CoFactor(R) for the Treatment of Advanced Breast Cancer
5. ADVENTRX to Present ANX-201 Preclinical Data at Keystone Symposia HIV Pathogenesis Conference
6. ADVENTRX to Present CoFactor Phase 2 Breast Cancer Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
7. ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study
8. ADVENTRX Presents CoFactor Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
9. ADVENTRX Announces CoFactor(R) Phase 2b Clinical Trial Overall Survival Results
10. ADVENTRX Announces Preliminary Response Rate Data From Discontinued Phase 3 Trial of CoFactor(R)
11. ADVENTRX Completes Patient Enrollment in ANX-514 Bioequivalence Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... , March 29, 2017  NuVasive, Inc. (NASDAQ: ... transforming spine surgery with minimally disruptive, procedurally-integrated solutions, ... 510(k) clearance of the CoRoent® Small Interbody™ System ... levels in the cervical spine. This marks the ... be used at up to four contiguous levels. ...
(Date:3/29/2017)... 29, 2017   Dynatronics Corporation (NASDAQ: ... of Cynthia L. McHenry (Cyndi) as ... for leading Dynatronics manufacturing, distribution, and purchasing operations ... Dynatronics, CEO Kelvyn H. Cullimore, Jr. ... search process conducted by the company as it ...
(Date:3/29/2017)... 2017 NetworkNewsWire Editorial Coverage  ... There are a ... regulating marijuana, but economic arguments also favor its legalization. The ... enforcement costs. However, to legalize and regulate marijuana requires an ... (OTC: SING) ( SING Profile ), American Cannabis Company (OTC: ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... March 29, 2017 , ... Physicians’ ... a specialized continuing medical education conference for clinicians who manage some of the ... New York. , The program will be led by co- chairs Dr. ...
(Date:3/28/2017)... , ... March 28, 2017 , ... ... that in order to improve teacher quality, the field must first improve teacher ... one popular reform to the next” and that decades of input- and outcome-based ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... Ruel Williamson brings his extensive knowledge of appraisals, property values, ad valorem taxation, ... real estate valuation industry for more than 40 years. , “Ruel is a ...
(Date:3/28/2017)... ... March 29, 2017 , ... Dr. Isabella Wentz, PharmD, FASCP, one of ... series titled The Thyroid Secret. Dr. Wentz talked about journey and research recently on ... that medication IS NOT the only solution to deal with thyroid disease. , ...
(Date:3/28/2017)... ... March 28, 2017 , ... Via Oncology, the ... launch of a free, public-facing tool for analyzing the costs of various drug ... provide comparative information to patients, providers, insurers and pharmaceutical companies about the estimated ...
Breaking Medicine News(10 mins):